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Abstract Pharmacological thromboprophylaxis (TP) is
known to reduce venous thromboembolism (VTE) in
medical inpatients, but the criteria for risk-driven pre-
scription, safety and impact on mortality are still debated.
We analyze data on elderly patients with multimorbidities
admitted in the year 2010 to the Italian internal medicine
wards participating in the REPOSI registry to investigate
the rate of TP during the hospital stay, and analyze the
factors that are related to its prescription. Multivariate
logistic regression, area under the ROC curve and CART
analysis were performed to look for independent predictors
of TP prescription. Association between TP and VTE,
bleeding and death in hospital and during the 3-month post-
discharge follow-up were explored by logistic regression
and propensity score analysis. Among the 1,380 patients
enrolled, 171 (15.2 %) were on TP during the hospital stay
(162 on low molecular weight heparins, 9 on fondaparinux).
The disability Barthel index was the main independent
predictor of TP prescription. Rate of fatal and non-fatal
VTE and bleeding during and after hospitalization did not
differ between TP and non-TP patients. In-hospital and
post-discharge mortality was significantly higher in patients
on TP, that however was not an independent predictor of
mortality. Among elderly medical patients there was a rel-
atively low rate of TP, that was more frequently prescribed
to patients with a higher degree of disability and who had an
overall higher mortality.
Keywords Thromboprophylaxis  Venous
thromboembolism  Medical patients
Introduction
Large population-based cohort studies agree that the inci-
dence of venous thromboembolism (VTE) is around 1 per
1,000 person-year in the overall population, but up to 6
times higher in the elderly [1, 2]. In the elderly VTE is
frequently associated with recent hospitalization or
immobilization and the presence of chronic cardio-pul-
monary diseases [3]. Advancing age and age-related mul-
timorbidity also represent a risk factor for more severe
VTE, with a higher proportion of pulmonary embolism
(PE) over isolated deep vein thrombosis (DVT, and a
higher mortality rate [2, 4, 5]. Furthermore, elderly patients
with VTE less likely complain of typical symptoms [3] and
frequently have high D-dimer levels at baseline [6], thus
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making the diagnostic process more difficult. Hence,
acutely ill elderly medical patients represent a pivotal tar-
get for strategies of VTE prevention. Risk assessment
models assign a low weight to advanced age when it is the
only risk factor for VTE [7–10], but elderly patients often
present clusters of high-risk conditions for VTE which
make them strong candidates for pharmacological throm-
boprophylaxis (TP). By contrast, international registries on
modalities and frequencies of TP use [11, 12] show a low
rate of prescription even in hospitalized medical patients
who meet the guideline recommendations [13]. Retro-
spective registries on patients with VTE show that only
30–40 % of the elderly have received TP [3], and as few as
20 % of those older than 90 years [5]. All the registries
clearly show that advanced age is also a risk factor for
bleeding during therapeutic or prophylactic anticoagulation
[14, 15]. The need to balance the thrombotic and bleeding
risks is reflected by the most recent scientific guidelines
that, rather than making detailed indications for TP in
nonsurgical settings, recommend a balanced evaluation of
the risks of thrombosis and bleeding [16, 17]. Such
guidelines framed on caution, together with the practical
difficulty to assess a risk/benefit balance, may partly
explain the widespread underuse of TP.
To improve practice in this field, more knowledge on the
frequency and modalities of TP prescription in acutely ill
elderly medical patients is needed, particularly in those
with multimorbidity who are often excluded from ran-
domized clinical trials. Pursuing this primary objective,
this study evaluated the prescription rate of TP in elderly
patients admitted to Italian internal medicine wards par-
ticipating in the REPOSI registry, and which were the risk
factors associated with physicians’ decision. We also tried
to investigate, within the limits of an observational design,
the association between TP prescription and the occurrence
of such events as bleeding and death during the hospital
stay and at 3-month post-discharge follow-up.
Methods
Data collection
We analyzed the data collected from January to December
2010 during the annual data collection for REPOSI
(REgistro POliterapie Societa` Italiana di Medicina Interna)
[18], a prospective registry stemming from the collabora-
tion between the Italian Society of Internal Medicine and
the Mario Negri Institute for Pharmacological Research.
Patients were eligible for REPOSI if: (1) they were
admitted to one of the participating wards during the 4
index weeks chosen for recruitment (one per season); (2)
their age was C65 years; (3) gave informed consent. A
web-based case report form (CRF) was filled with data on
socio-demographic and clinical parameters, reasons for
hospital admission, diagnoses at admission and discharge,
clinical events and main laboratory data occurring in hos-
pital and pharmacotherapy at admission, in hospital and at
discharge. Diseases were coded according to the Interna-
tional Classification of Diseases, 9th Revision, Clinical
Modification [ICD-9-CM], Sixth Edition, World Health
Organization 1987, and summarized by indexes of multi-
morbidity burden and severity according to the Cumulative
Illness Rating Scale [CIRS] [19]: impairment of major
organ/systems is rated from 1 (no impairment) to 5 (life-
threatening impairment); the index of comorbidity is equal
to the number of impaired systems, with a scale of at least
3; the severity index corresponds to the mean degree of
impairment. Drugs were encoded according to the Ana-
tomical Therapeutic Chemical [ATC] classification sys-
tem); for each drug physicians filling the CRF were asked
to specify the dose prescribed. Additional functional data
were collected on the patient cognitive status according to
the Short Blessed test [20], presence of depression using
the Geriatric Depression Scale [21], and performance in
basic activities of daily living according to the Barthel
Index [BI] [22]. Finally, information on post-discharge
therapies and outcomes were collected by a follow-up
phone call 3 months after hospital discharge.
Study population and TP definition
We defined patients prescribed with pharmacological TP
those on treatment with subcutaneous low molecular
weight heparin (LMWH), low-dose unfractionated heparin
(UFH) or fondaparinux during the hospital stay, provided
that VTE prophylaxis was reported as the reason for pre-
scription regardless of the drug and dose administered.
Patients on LMWH/UFH/fondaparinux during the hospital
stay for reasons different from TP and patients on therapy
with vitamin K antagonists (VKA) were excluded from the
study population.
Statistical analyses
Factors associated to TP prescription. Whether and which
possible risk factors for VTE [7–10, 23–25] were associ-
ated to TP prescription was investigated. The effect of
some risk factors for bleeding possibly associated to lack of
prescription was also explored; Table 1 shows the variables
evaluated. Since the data collected in REPOSI did not
include specific information on reduced mobility/con-
strained bed rest, as an alternative we tried to evaluate the
relationship between TP prescription and such a measure of
patient performance status as the Barthel Index (BI) cal-
culated at admission. The BI is calculated upon ten items
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(stool and urinary incontinence, help needed with groom-
ing, toilet use, bathing, feeding, transfers, walking, dressing
and climbing stairs) and is expressed as a score of 0–100, a
score lower than 50 being associated with total-severe
impairment. We separately evaluated as predictors the
global BI and the score for BI items more directly related
Table 1 Characteristics of
patients on thromboprophylaxis
(TP) or not during hospital stay
a It includes rheumatological
disorders (such as rheumatoid
arthritis, diffuse collagen
diseases and vasculitis), lupus
anticoagulant (ICD-9 286.5) and
other coagulation disorders
(ICD-9 790.92),
myeloproliferative syndromes
b Malignancy was considered
as risk factor independently of
its activity since informative
data were not available
Patients on
TP
(n = 171)
Patients not
on TP
(n = 950)
p value
Male, n (%) 65 (38.0) 483 (50.8) 0.002
Mean age (SD), years 81.4 (7.5) 78.4 (7.3) \0.001
Mean BMI (SD), kg/m2 28.0 (32.9) 27.5 (17.8) 0.136
Mean duration of hospital stay (SD), days 16.5 (28.1) 10.5 (8.1) \0.001
Mean Barthel index score (SD) 56.5 (36.2) 80.0 (28.7) \0.001
Barthel index score \50, n (%) 75 (44.4) 147 (15.7)
Barthel mobility items score B3, n (%) 84 (49.7) 167 (17.7)
Clinical history
Mean CIRS severity index score(SD) 1.7 (0.3) 1.6 (0.3) 0.049
Mean CIRS co-morbidity index score (SD) 3.0 (1.8) 2.8 (1.7) 0.218
Congestive heart failure, n (%) 31 (18.1) 120 (12.6) 0.053
Chronic pulmonary disease, n (%) 49 (28.6) 233 (24.5) 0.252
Malignancy, n (%) 38 (22.2) 182 (19.2) 0.353
Chronic renal insufficiency, n (%) 27 (15.8) 148 (15.6) 0.944
Previous VTE, n (%) 8 (4.7) 28 (2.9) 0.273
Hospitalization for VTE during 6 months
before admission, n (%)
1 (0.6) 5 (0.5) 0.923
Chronic venous insufficiency, n (%) 8 (4.7) 21 (2.2) 0.061
Thrombophiliaa, n (%) 2 (1.2) 27 (2.8) 0.205
Reasons of hospital admission
Decompensated/acute heart failure, n (%) 21 (12.3) 59 (6.2) 0.005
Decompensated COPD, n (%) 7 (4.1) 22 (2.3) 0.178
Acute respiratory failure (including pneumonia), n (%) 12 (7.0) 13 (1.4) \0.001
Septicemia/sepsis, n (%) 3 (1.7) 11 (1.2) 0.518
Active cancer, n (%) 3 (1.7) 41 (4.3) 0.112
Ischemic stroke/TIA, n (%) 4 (2.3) 24 (2.5) 0.885
Treatments at admission
Antitumoral chemotherapy, n (%) 4 (2.3) 17 (1.8) 0.625
Estro-progestogen therapy (tamoxifen included), n (%) – 1 (0.1) 0.671
Factors possibly affecting TP prescription
History of bleeding, n (%) 6 (3.5) 37 (3.9) 0.809
History of intracranial bleeding, n (%) 1 (0.6) 6 (0.6) 0.943
Hospitalization for bleeding during 6 months before
admission, n (%)
2 (1.2) 14 (1.5) 0.758
Hospitalization for intracranial bleeding during 6 months
before admission, n (%)
– 1 (0.1) 0.671
Actual hospitalization for bleeding, n (%) 2 (1.2) 31 (3.3) 0.136
Actual hospitalization for intracranial bleeding, n (%) – 1 (0.1) 0.671
Mean platelet count (SD) at admission, 103/mm3 252.1 (102.3) 227.7 (128.9) \0.001
Platelet count \130 9 103/mm3, n (%) 13 (7.6) 134 (14.1) 0.020
Antiplatelet therapy, n (%) 74 (43.3) 406 (42.7) 0.896
ACCP2004/2008 criteriab for TP prescription, n (%) 60 (35.1) 133 (14.0) \0.001
Padua Scoreb, median (range) 4 (0–9) 2 (0–11) \0.001
Padua Scoreb C4, n (%) 104 (60.8) 332 (34.9) \0.001
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to patient global mobility (transfer and walking items), a
reduced mobility being accounted for when the score for
transfer or walking items was B3. Patients on TP or not
during the hospital stay were compared for the distribution
of the putative predictors and risk factors according to
Pearson Chi squared (categorical variables) or Mann–
Whitney (continuous variables) tests. Multivariate logistic
regression (p value for retaining\0.05) with the evaluation
of area under the ROC curve (c-statistics) was performed to
identify independent predictors of TP prescription. The
logistic results were confirmed and depicted by a Classi-
fication and Regression Tree (CART) analysis [26]. The
latter is a non-parametric technique used to hierarchically
select among a large number of variables those that better
split the population between patients who experienced or
not the outcome of interest (receiving or not TP, in this
study), exploring also the reciprocal interactions between
covariates. Those variables are represented as splitting
knots from which one branch springs up for each value of
the variable associated with a different probability of the
outcome for each terminal branch (a branch not followed
by any knot) a measure of the relative risk of outcome is
provided. Finally, to allow a comparison with the results of
previous registries [11, 12] the frequency of TP prescrip-
tion was recalculated using as denominator the patients
who would have met the prescription guidelines of the
American College of Chest Physicians (ACCP), 7th edi-
tion, 2004 [13] (chosen because they were used as refer-
ence in previously published international registries on TP
[11, 12]), and the criteria for high risk of VTE according to
the Padua Prediction Score [9] suggested by the most
recent ACCP guidelines [17]. Also for the ACCP 2004
criteria and for the Padua score, the ‘‘reduced mobility’’
definition was substituted by the BI mobility items as
mentioned above. In addition, the discriminative power
(c-statistics) of the ACCP 2004 criteria and the Padua
Score was calculated in the population.
TP and outcomes. Patients on TP or not during the
hospital stay were compared for the occurrence of the
following outcomes: VTE events (overall and fatal),
bleeding events (overall and fatal), and death for any cause
occurring during hospital stay or during the 3-month post-
discharge follow-up. The REPOSI database did not allow
an accurate classification of non-fatal bleeding as major or
minor, but any such event occurring during follow-up was
defined as having or not caused hospitalization. Only those
patients for whom data on 3-month follow-up were avail-
able were included in the analyses on post-discharge out-
comes. In order to selectively evaluate the effect on post-
discharge outcomes of TP administered during the hospital
stay, these analyses were repeated excluding patients pre-
scribed with TP at discharge. In consideration of the rela-
tive short duration of the observation time, the association
between TP and outcomes was looked at by logistic
regression models. Being the factors associated to TP
prescription potentially associated to death for any cause,
mortality analyses were adjusted for those factors behav-
ing as confounders by performing multivariate logistic
regressions, and also according to a propensity score
analysis for TP [27] calculated including the risk factors
found to be associated to TP prescription in the previous
analyses. The average treatment effect on the treated
(ATT) was calculated using the Kernel matching method
with bootstrapped standard errors.
Additional analyses on TP at discharge. Patients pre-
scribed with TP at discharge were compared to patients not
prescribed (irrespective of whether they were on TP during
the hospital stay) for the occurrence of non-fatal and fatal
VTE and bleeding events during follow-up.
In order to take into account the multi-center origin of
the REPOSI data, we adopted robust variance estimates,
obtained in all regression models by the Huber/White/
sandwich estimator that considers observations as inde-
pendent across groups (the REPOSI centers in this case).
STATA was used to perform all the analyses (version 9.2
and 11, Statacorp, College Station, Tx, US).
Results
During 2010, 1,380 patients were enrolled in REPOSI
(mean age 79.0 ± 7.3 years; median 79.1 years, range
65.0–101.4 years). After excluding those on LMWH/UFH/
fondaparinux during the hospital stay for reasons other than
TP and those on therapy with VKA, 1121 REPOSI patients
were included in these analyses (median age 82, range
65–101 years; 49 % males). The median number of mor-
bidities diagnosed per patient at admission was 5 (range
1–21), with a median CIRS comorbidity index of 3/13
(range 0–8) a median CIRS severity index of 1.6 range
(1–2.7). The median number of drugs taken per patient at
admission was 5 (range 1–15). Among those 1,121 patients,
171 (15.2 %, or 12.4 % when considering all the REPOSI
2010 population) were on TP; 158 were on LMWH, 4 on
UFH, 9 on fondaparinux. The flow chart in Fig. 1 summa-
rizes the primary study population and sub-populations.
Predictors of TP prescription
Table 1 compares patients prescribed or not with TP with
respect to general demographic and clinical characteristics,
with particular emphasis on those that may have influenced
prescription. In univariate logistic regressions, the follow-
ing characteristics were associated with TP prescription/
non prescription during the hospital stay (listed in
decreasing order of AUC value): BI (AUC 0.709 for
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continuous variable, 0.643 for dichotomized variable with
50 as cut-off, 0.660 for BI mobility items score C or \3),
length of hospital stay (AUC 0.625), age (AUC 0.616 for
continuous variable, 0.606 for 80 years old dichotomized
variable), platelet count (AUC 0.581 for continuous vari-
able, 0.532 for dichotomized variable with 130 9 103/mm3
as cut-off), gender (AUC 0.564), CIRS severity index
(AUC 0.547), admission for acute heart failure (AUC
0.530) and for acute respiratory failure (AUC 0.528).
Table 2 shows the multivariate logistic model (AUC for
the model 0.759). Similar results were obtained using the
global BI or only the mobility BI items. The inclusion of
the BI interaction term for each of the other variables
allowed the demonstration that some risk factors were
differently associated to TP in patients with or without
performance or mobility impairment: gender was signifi-
cant only in patients with a BI\50; age, length of hospital
stay and admission for acute heart or respiratory failure
were significant only in patients with a BI C50. These
findings were generally confirmed by the CART analysis
(Fig. 2). The tree shows that, taking a relative prescription
ratio (RPR) of 1 as equipoise for TP prescription, patients
with a low global BI (same results for a low BI mobility
score) were more likely to receive TP (with a slight dif-
ference in probability between men and women); and that
among patients with a higher BI (52–100), those staying in
hospital for a long time or those admitted for acute respi-
ratory failure (if not completely well performing, i.e., BI of
99–100) were still likely to receive TP. Age, both as con-
tinuous and dichotomized variables (using 80 or 70 years
old as cut-off), was not retained as a discriminating vari-
able in the CART analysis.
Prescription adherence to ACCP 2004 guidelines
and the Padua prediction score
Only 14.9 % (17.2 % when a history for malignancy was
considered a risk factor) of the 1,121 patients included in
our study met the criteria for TP prescription according to
the ACCP 2004 guidelines, 29.3 % (or 31.1 % when a
history for malignancy was considered a risk factor) of
those being actually prescribed with TP. The AUC for the
ACCP 2004 criteria as predictor of TP prescription was
0.581, 95 % confidence interval (CI) 0.545–0.617 (or
0.605, 95 % CI 0.568–0.643, when a history for malig-
nancy was considered a risk factor). 28.9 % of patients
(39.9 % when a history for malignancy was considered a
risk factor) met the criteria for high risk of VTE according
to a Padua prediction score C4; 27.5 % (or 23.8 % when a
history for malignancy was considered a risk factor) of
those were prescribed with TP. The c-statistics for the
Padua prediction score as predictor of TP prescription was
higher: AUC 0.676 (95 % CI 0.634–0.717) or 0.686 (95 %
CI 0.645–0.726) when used as continuous score, depending
on the inclusion or not of all patients with a history of
malignancy; 0. 629 (95 % CI 0.590–0.669) or 0.636
(0.597–0.676) when used as C or \4 prescribing rule,
depending the inclusion or not of all patients with a history
of malignancy.
TP and outcomes
During hospital stay, 6 patients among the 1,121 analyzed
developed an isolated DVT (none a PE); 1 (0.6 % of them)
was on TP and 5 (0.5 %) were not (p value = 0.923).
Nineteen patients bled during the hospital stay; 3 (1.7 %)
Fig. 1 Study population. Pts patients, LWMH low weight molecular
heparin, UFH unfractionated heparin, VKAs vitamin K antagonists,
TP thromboprophylaxis, FUP follow-up
Table 2 Predictors of thromboprophylaxis prescription (multivariate
logistic regression)
Covariate OR (95 % CI) p value
Barthel Index score \50a 3.74 (2.57–5.46) \0.001
Sex (male vs. female) 0.69 (0.48–0.99) 0.049
Age [80 years olda 1.60 (1.10–2.32) 0.013
Length of hospital stay (days) 1.03 (1.02–1.05) \0.001
Admission for acute heart failure 2.16 (1.22–3.83) 0.008
Admission for acute respiratory failure 5.81 (2.00–11.54) \0.001
Platelet count \130 9 103/mm3a 0.51 (0.27–0.97) 0.040
BI Barthel Index, OR Odds Ratio, CI confidence interval
a For simplicity of interpretation the model with dichotomized vari-
ables is presented. When for age a dichotomized variable with
70 years as cut-off was included (for analogy to the Padua Prediction
Score), age was no longer statistically significant
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were on TP and 16 (1.7 %) were not (p value = 0.948).
Among these one patient, not receiving TP, experienced
both a non-fatal VTE and bleeding event. Four of the 722
patients followed up after discharge experienced a VTE
event during the 3 months of follow-up; one (1.0 %) of
them was on TP in hospital and 3 (0.5 %) were not
(p value = 0.553). Two of them, 1 on TP in hospital
(1.2 %) and 1 without (0.2 %), had fatal pulmonary
embolisms (p value 0.207). Nine patients experienced
bleeding (4 causing hospitalization) during the 3 months of
follow-up; 3 (2.9 %) of them were on TP in hospital and 6
(1.0 %) were not (p value = 0.121). Two of them, 1 on TP
in hospital (1.2 %) and 1 without (0.2 %), had fatal hem-
orrhages (p value 0.207). Similar results were obtained for
outcomes at follow-up after excluding patients prescribed
with TP at discharge.
Fifty of the 1,380 (3.6 %) patients and 39 of the 1,121
(3.5 %) included in our analyses died in hospital for any
cause. In particular, 15/171 (18.1 %) of patients receiving
TP and 24/950 (2.5 %) of those not on TP died in hospital
(OR for univariate analysis 3.7, 95 % CI 1.9–7.2,
p \ 0.001). After adjusting with variables found to be
associated both to TP prescription and hospital death for
any cause (in univariate logistic analyses), TP prescription
was no longer independently associated to death (Table 3a).
Propensity score analysis confirmed these results, showing a
non-significant difference for the occurrence of outcomes
between patients receiving or not receiving TP during the
hospital stay after adjustment for the probability to receive
TP (Table 3a).
Eighty-two of the 899 patients (9.1 %) with available
follow-up data and 68 of the 722 (9.4 %) included in our
analyses died during the 3 months after discharge. In par-
ticular, 19/104 (18.3 %) of those receiving TP during the
hospital stay and 49/618 (7.9 %) of those not receiving TP
died in hospital (OR for univariate analysis 2.6, 95 % CI
1.5–4.6, p = 0.001). Because patients with available fol-
low up data were a sample different from that of the pri-
mary analysis, we explored again in this group which
factors were associated to in-hospital TP prescription. After
adjusting for variables found to be associated to both in
hospital TP prescription and death (in univariate logistic
analyses), TP remained statistically significantly associated
to death (Table 3b). Propensity score analysis failed to
confirm these findings, even if the ATT was close to sta-
tistical significance (Table 3b).
No significant association was found between TP pre-
scription and death due to VTE or death due to bleeding, in
hospital and after discharge.
Additional analyses on TP at discharge. After excluding
patients discharged on LWMH/UFH/fondaparinux for
reasons different from TP and patients on VKAs, 704 were
included in this additional analysis: 24/704 (3.4 %) were
discharged from the hospital with a TP prescription, two of
them in critical conditions; six of them were not prescribed
TP in hospital. None of the patients discharged on TP
experienced VTE during follow-up, whereas 4 (0.6 %)
total events (p value for Pearson v2 = 0.142), with 2
(0.3 %) fatal PE (p value for Pearson v2 = 0.071) occurred
in patients not prescribed TP. In 1 of 24 patients (4.2)
N F RPR
BI
99-100 349 11 .20
<24 BI
no 445 56 .81
52-98 Admission for ARF
yes 11 4 2.34
52-100 Length of hospital stay (days)
24 54 19 2.27
male 87 21 1.56
0-51 gender
female 137 57 2.68
Fig. 2 Multivariate Classification and Regression Tree (CART)
analysis. Only those variables found to be significantly related to
VTE prophylaxis in univariate logistic regression were included in the
analysis: gender, age (continuous), Barthel Index (continuous), length
of hospital stay (continuous), CIRS severity, admission for acute heart
failure or acute respiratory failure, platelet count at admission. The
analysis retains only the best discriminating variables and models
them hierarchically, by finding for continuous variable the best-
splitting cut-point. N number, F Failures, RPR Relative Prescription
Ratio, BI Barthel Index, ARF Acute Respiratory Failure
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discharged on TP a bleeding event was fatal, compared to
8/680 (1.2 %) total bleeding events and 1/680 (0.1 %) fatal
event among patients discharged not on TP
(p value = 0.231, for total events; p value = 0.018, for
fatal events). TP prescription at discharge remained sta-
tistically significantly associated to death due to bleeding
even after adjusting for risk factors for TP prescription.
Discussion
Using data stemming from a registry, this study has shown
that less than one-fifth of the more than 65 years old
patients with multimorbidity and polipharmacy admitted to
70 internal medicine wards in Italy were prescribed TP in
hospital. Among the putative risk factors considered,
impaired global performance as measured by the Barthel
Index and, to a lesser degree, the duration of hospital stay
and hospitalization due to clinical conditions leading to
acute respiratory failure were the main independent pre-
dictors of TP prescription. No statistically significant
association was found between TP prescription and out-
come, but patients receiving compared to those not
receiving TP had more frequent fatal and non-fatal bleed-
ing events during the 3 months of post-discharge follow-
up, as well as a higher mortality for any cause both in
hospital and after discharge.
The hierarchy of factors associated to TP prescription
found in this analysis is quite consistent with the Padua
Risk Score, that assigns a higher weight to reduced
mobility (3 points) compared to medical conditions such as
heart or respiratory failure (1 point). Likewise, the most
recent ACCP guidelines [17] that recommend to use the
Padua Risk Score to stratify the risk of VTE in medical
patients mark a shift towards the attribution of a higher
importance to reduced mobility as risk factor, in compar-
ison to previous ACCP guidelines [13, 24]. Notwithstand-
ing, not only the ACCP 2004 criteria but also the Padua
Risk Score had a poor to fair predictive ability for TP
prescription among REPOSI patients. The REPOSI study
collects data from an unselected setting aimed to be rep-
resentative of the elderly patients with multimorbidity
populating the internal medicine wards. Actually, our
sample of patients typically represents the conditions of
multimorbidity and polipharmacy [28, 29]. Hence our
findings point out the difficult application of prediction
schemes, even when validated, in such a really complex
and increasing patient population.
The complex clinical setting of multimorbidity may also
explain the low rate of TP prescription in REPOSI patients.
The different clinical setting for our study (an elderly
population, with probably a higher representation of frail
patients) compared to those of the IMPROVE study [11]
and the ENDORSE registry [12], may explain the lower
rate of TP, considering as denominator the overall study
population (15 % in our study and about 60 % in the
IMPROVE) or only the patients who met the criteria for TP
prescription according to the ACCP 2004 guidelines [13]
(30 % in our study, 40 % in ENDORSE, 33 % among
IMPROVE patients from United States, 47 % among those
from other countries). A higher degree of frailty and clin-
ical complexity might increase physician’s concerns about
Table 3 Thromboprophylaxis
and death for any cause:
multivariate logistic regression
and propensity score analysis
a Average treatment effect on
the treated using Kernel
matching method with
bootstrapped standard errors
Covariate OR (95 % CI) p value
Multivariate logistic regression
(a) Death during the hospital stay
TP during the hospital stay 1.84 (0.88–3.85) 0.107
Age (continuous) 1.03 (0.98–1.08) 0.187
Barthel Index score (continuous) 0.98 (0.97–0.99) \0.001
CIRS severity index score 4.10 (1.59–10.55) 0.003
Admission for acute respiratory failure 3.24 (0.98–10.70) 0.053
Propensity score analysis ATTa (se) t
All covariates 0.034 (0.026) 1.283
(b) Death during the post-discharge follow upX
TP during the hospital stay 2.15 (1.11–4.17) 0.023
Age (continuous) 1.03 (0.99–1.07) 0.084
Sex (male vs. female) 2.98 (1.64–5.41) \0.001
Barthel Index score (continuous) 0.98 (0.97–0.99) \0.001
CIRS severity index score 1.93 (0.86–4.31) 0.109
Platelet count \130 9 103/mm3 2.10 (1.07–4.13) 0.031
Propensity score analysis ATTa (se) t
All covariates 0.044 (0.023) 1.886
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anticoagulant safety. Was concern about safety the reason
for under-prescription of TP in REPOSI patients? Recent
bleeding or potential risk factors for bleeding were less
frequent in patients on TP. On the other hand, REPOSI
physicians sometimes continued TP after discharge, in
spite of the fact that published data not only fail to show a
benefit of extended pharmacological TP, but also find it to
increase the risk of bleeding [30]. Our additional analysis
on TP prescribed after discharge confirmed the association
between prolonged TP and risk of bleeding. However, it
also confirmed that in hospitalized patients the risk of VTE
persisted after hospital discharge, with lower rates of VTE
occurrence in patients prescribed with TP after discharge.
Perhaps the physician’s concern to discharge patients who
did not regain acceptable performance has become more
compelling than available guidelines. Notwithstanding, the
kind of analyses performed in REPOSI is unable to capture
the physician’s perception of a high risk of VTE or
bleeding and can allow only to speculate on the actual
physician’s risk aversion. Moreover, we could not sys-
tematically include in the analysis many aspects that the
physician may have taken into account in the choice:
practical issues, patient preferences, hospital changes in
clinical conditions, risk/benefit balances in patients with a
poor prognosis.
We recognize that our study has relevant limitations.
First, since the registry was not specifically designed to
answer the question of TP and is based on chart records, a
certain degree of underreporting is plausible. Underre-
porting might have involved the risk factors for VTE; this
limitation, together with the inability of Barthel Index to
capture the cases of reduced mobility prescribed by the
physician, might have led to underestimate the percentages
of patients classifiable at high risk for VTE according to the
ACCP 2004 or Padua criteria. Also some data on TP pre-
scription might be missing, so that a 15 % rate of pre-
scription in the whole REPOSI population may represent
an underestimation; conversely, since there is no reason for
a non-random underreporting of risk factors and TP pre-
scription, this limitation might have affected less the esti-
mate of the proportion of TP among high risk patients
(about 30 %). Because of the forementioned limitations in
design, the rate of VTE and bleeding events was definitely
lower than expected for such a high-risk population. The
rate of VTE was similar to that of symptomatic events
according to published trials [31]. As to the rate of
bleeding, in the IMPROVE study the rate of bleeding was
slightly higher than in our study, both in patients on TP and
in those not [15]. Another important limitation is repre-
sented by the observational setting. Confounding by indi-
cation is a common problem for observational studies on
treatment, because treatments are most often indicated in
patients at high risk of poor outcomes, so that these studies
may fail to demonstrate the efficacy of a drug or even find a
relative harm [32, 33]. Therefore, we recognize the
inability of this study to reliably conclude about any causal
association between TP and outcome [34]. Nevertheless,
we recognize the observational and clinical value of our
findings concerning the tendency in patients prescribed
with TP for a higher frequency of bleeding and, even more
evidently, for a higher mortality, in hospital and after dis-
charge, compared to those not prescribed.
In conclusion, it appears that TP prescription in elderly
patients with multimorbidity cannot be confined to a
problem of mere adherence to guidelines. Even if the
overall rate of prescription was low and the predictive
ability of guiding criteria not satisfying, a higher throm-
botic risk profile was observed in patients prescribed versus
those not prescribed with TP. Thus, the overall low rate of
TP use cannot be unequivocally explained, but we
hypothesize that in these patients the difficulty to prioritize
among the several therapeutic needs, and not simply the
fear of provoking bleeding, may explain the poor adher-
ence to guidelines. In this context [35], an individualized
patient management, where the physician joins scientific
knowledge to the accurate evaluation of the patient, may be
still the most recommendable in this setting, rather than a
generalized ‘‘MUST’’ strategy [36].
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